The global chronic pulmonary hypertension treatment market is expected to garner a market value of USD 7 billion in 2023 and is expected to accumulate a market value of USD 11.4 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for chronic pulmonary hypertension treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.
The chronic pulmonary hypertension treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The global Chronic Pulmonary Hypertension Treatment market is expected to grow at a significant rate in the coming years due to an increasing prevalence of chronic PH and a growing demand for effective treatments. Factors such as rising healthcare expenditure and increasing awareness about the disease are also expected to drive market growth.
The market for chronic pulmonary hypertension treatment includes a range of products and services such as Medications, Oxygen therapy, Surgery, Lifestyle modifications and so on.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | USD 7 billion |
| Anticipated Forecast Value (2033) | USD 11.4 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Chronic Pulmonary Hypertension Treatment reflected a value CAGR of 3.5% during the historical period, 2018 to 2022. Patients with chronic PH require long-term treatment to manage their symptoms and improve their quality of life. As a result, there is a high demand for drugs and therapies that can effectively manage the disease.
The market is also expected to grow due to rising healthcare expenditure and increasing awareness about the disease. Governments and healthcare organizations are investing heavily in the development of new and improved treatments for chronic PH, which is expected to drive market growth. Furthermore, initiatives to raise awareness about the disease and improve early detection and diagnosis are also expected to contribute to market growth.
The development of new drugs and therapies is also expected to drive market growth. Pharmaceutical companies are investing heavily in research and development to develop new and innovative treatments for chronic PH. Overall, the market for Chronic Pulmonary Hypertension Treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Increasing incidence of chronic brain injuries to push the market growth
The chronic pulmonary hypertension treatment market is expected to experience significant growth in the coming years due to several factors. Chronic PH is a serious and life-threatening condition that affects the blood vessels in the lungs, causing high blood pressure and putting a strain on the heart. The disease can have a significant impact on the quality of life of patients and can lead to complications such as heart failure, respiratory failure, and death.
According to a report by the Centers for Disease Control and Prevention (CDC), the prevalence of PH in the United States is approximately 1% of the adult population, and the prevalence is increasing. The increasing prevalence of PH is attributed to various factors such as aging population, environmental pollution, smoking, and other medical conditions such as lung diseases, heart diseases, and connective tissue disorders.
As the prevalence of chronic PH increases, there is a growing demand for effective treatments that can help manage the disease and improve the quality of life of patients. This demand is driving the growth of the chronic pulmonary hypertension treatment market, as pharmaceutical companies are investing heavily in the development of new and innovative treatments for the disease.
Furthermore, initiatives to raise awareness about chronic PH and improve early detection and diagnosis are also contributing to market growth. Governments and healthcare organizations are investing in programs to educate healthcare providers and the general public about the disease and its risk factors, which is expected to lead to earlier detection and treatment of the disease.
In summary, the increasing prevalence of chronic pulmonary hypertension is a major driver of the growth of the chronic pulmonary hypertension treatment market, as there is a growing demand for effective treatments to manage the disease and improve the quality of life of patients.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
The cost of treatment for chronic pulmonary hypertension is often high and can be a significant barrier to accessing care. The high cost of drugs, diagnostic tests, and medical procedures can make it difficult for patients to afford treatment, especially in low-income countries or for uninsured patients.
Furthermore, while there are several treatments available for chronic pulmonary hypertension, there is still a significant unmet need for more effective and targeted therapies. Some patients may not respond well to existing treatments, and there is a need for new drugs and treatment strategies that can improve outcomes for these patients.
Increasing Prevalence of the Condition shaping landscape for Chronic Pulmonary Hypertension Treatment
The chronic pulmonary hypertension treatment market in the South & East Asia region is expected to experience significant growth in the coming years. This growth can be attributed to several factors, including the increasing prevalence of chronic pulmonary hypertension in the region and the growing demand for effective treatments.
South & East Asia is home to a large and growing population, and the region has a high burden of cardiovascular and respiratory diseases, which are risk factors for chronic pulmonary hypertension. According to a report by the Asia Pacific Society of Respirology, the prevalence of pulmonary hypertension in Asia is estimated to be between 15 to 25 cases per million population, and this prevalence is expected to increase in the coming years.
The demand for effective treatments for chronic pulmonary hypertension is also growing in the region. There is increasing awareness about the disease among healthcare providers and patients, which is leading to earlier diagnosis and treatment. The growing availability of treatment options, including drugs and medical devices, is also contributing to market growth.
Several pharmaceutical companies are investing in the development of new and innovative treatments for chronic pulmonary hypertension, which is expected to further drive market growth. For example, in 2020, United Therapeutics Corporation announced the launch of Tyvaso in Japan, a new inhaled treatment for pulmonary arterial hypertension.
Increasing Focus on technological advancements Shaping Landscape for Chronic Pulmonary Hypertension Treatment in North America
North America is anticipated to acquire a market share of about 40% in the forecast period. The prevalence of chronic pulmonary hypertension is increasing in North America, which is driving demand for effective treatments. According to a report by the Centers for Disease Control and Prevention (CDC), approximately 10-15% of people in the United States with chronic obstructive pulmonary disease (COPD) also have pulmonary hypertension.
Advances in technology have led to the development of new and improved treatments for chronic pulmonary hypertension. For example, the introduction of prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors have revolutionized the treatment of pulmonary hypertension.
Overall, the chronic pulmonary hypertension treatment market in North America is expected to continue to grow due to the increasing prevalence of the disease, advancements in technology, government initiatives, increasing investments in research and development, and the growing aging population.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Oral Medications to hold a significant share and push market growth
The oral segment is likely to account for a significant share of the market. This is because oral medications are more convenient and easier to administer compared to other routes of administration. They are also generally preferred by patients over injections or inhaled medications. Several oral medications such as endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogs are currently available for the treatment of chronic pulmonary hypertension.
In addition, the growing prevalence of chronic pulmonary hypertension, coupled with the increasing demand for effective treatments, is expected to drive the growth of the oral segment in the coming years.
Hospital Pharmacies to take the lead and drive market growth
Hospital pharmacies are likely to account for a significant share of the market. This is because hospital pharmacies are often the first point of contact for patients with chronic pulmonary hypertension, and they play a critical role in the management and treatment of the disease. Hospitals also have access to a wider range of medications and are more likely to have specialized pulmonary hypertension treatment centers and clinics.
In addition, hospital pharmacies often work closely with healthcare providers to ensure that patients receive the appropriate medications and dosages, and they may also provide education and support to patients and their families.
Key players in the market include companies such as Bayer, Attgeno AB, Cereno Scientific AB, Bial - Portela C S.A, Liquidia Technologies, Bellerophon Therapeutics, AbbVie Therapeutics, Insmed, Altavant Sciences, Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., along with healthcare providers and technology companies among other global players.
In June 2022, Gossamer Bio, Inc., a clinical-stage biopharmaceutical company that specializes in discovering, acquiring, developing, and commercializing therapeutics in the areas of immunology, inflammation, and oncology, announced the release of crucial preclinical data that supports the potential of seralutinib in treating pulmonary arterial hypertension (PAH).
The article, titled "Inhaled Seralutinib Exhibits Potent Efficacy in Models of Pulmonary Arterial Hypertension," is available online and will be included in a future printed edition of the European Respiratory Journal, which is the premier scientific journal of the European Respiratory Society.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 7 billion |
| Market Value in 2033 | USD 11.4 billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Type, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Bayer, AG; Attgeno AB; Cereno Scientific AB; Bial - Portela C S.A; Liquidia Technologies; Bellerophon Therapeutics; AbbVie Therapeutics; Insmed; Altavant Sciences; Lupin Pharmaceuticals Inc.; Sun Pharmaceutical Industries Inc.; Teva Pharmaceutical Industries Ltd. |
| Customization | Available Upon Request |
The chronic pulmonary hypertension treatment market size is valued at USD 7 billion in 2023.
The chronic pulmonary hypertension treatment market is projected to thrive at a 5% CAGR through 2033.
The chronic pulmonary hypertension treatment market is predicted to surpass USD 11.4 billion by 2033.
The oral segment leads the route of administration in the chronic pulmonary hypertension treatment market.
North America will gain nearly 40% of the chronic pulmonary hypertension treatment market share by 2033.
1. Executive Summary | Chronic Pulmonary Hypertension Treatment Market 2. Market Overview 3. Market Background 4. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Injury Type 5.1. Traumatic injuries 5.2. Acquired injuries 6. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Diagnosis 6.1. Imaging studies 6.2. Blood tests 6.3. Brain evaluations 7. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 7.1. Occupational therapy 7.2. Physical therapy 7.3. Psychotherapy 7.4. Speech or language therapy 8. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 8.1. Hospitals 8.2. Neurology Clinics 8.3. Independent Pharmacies 9. Global Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. South Asia 9.5. East Asia 9.6. Oceania 9.7. MEA 10. North America Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Latin America Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Europe Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Oceania Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. MEA Chronic Brain Damage Management Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 17. Key Countries Chronic Brain Damage Management Market 18. Market Structure Analysis 19. Competition Analysis 19.1. NeuroVive Pharmaceutical AB 19.2. TEVA Pharmaceutical Industries Ltd. 19.3. Integra LifeSciences Corporation 19.4. Medtronic PLC 19.5. Neuren Pharmaceuticals Ltd. 19.6. Johnson & Johnson Services Inc. 19.7. Smith & Nephew 19.8. Stryker 19.9. B. Braun Melsungen AG 19.10. Neural Analytics, Inc. 20. Assumptions & Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Chronic Pulmonary Hypertension Treatment Market
